CAB Spotlight - Vijaya Jori | Johns Hopkins University Baltimore-India Clinical Trials Unit

CAB Spotlight - Vijaya Jori

Date: 04/01/2022

Community Advisory Boards are key members of research programs. The ACTG Newsletter features Vijaya Jori of the JHU-BJGMC CAB!

Efavirenz (EFV) is an anti-HIV medicine that is commonly used to treat HIV infection in adults and children older than 3 years...

1077BF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Primary Objective To obtain sputum, serum, urine, and peripheral blood mononuclear cells (PBMCs) for central TB biorepository...

The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a...

This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...